awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38908779-912BB9D4-A531-4A7D-B40E-504EBA559E2A
Q38908779-912BB9D4-A531-4A7D-B40E-504EBA559E2A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38908779-912BB9D4-A531-4A7D-B40E-504EBA559E2A
The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.
P2860
Q38908779-912BB9D4-A531-4A7D-B40E-504EBA559E2A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38908779-912BB9D4-A531-4A7D-B40E-504EBA559E2A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f848bd31543e9a6666beead53e6343e75b51916f
P2860
Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus